An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients

Tedesco-Silva, Helio; Saliba, Faouzi; Barten, Markus J.; De Simone, Paolo; Potena, Luciano; Gottlieb, Jens; Gawai, Apurva; Bernhardt, Peter; Pascual Santos, Julio

doi:http://dx.doi.org/10.1016/j.trre.2021.100655

An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients

License

Citation

Tedesco-Silva H, Saliba F, Barten MJ, De Simone P, Potena L, Gottlieb J, et al. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients. Transplant Rev (Orlando). 2022 Jan; 36(1):100655. DOI: 10.1016/j.trre.2021.100655

Abstract

As the risk of graft loss due to acute rejection has declined, the goal of post-transplant management has switched to long-term preservation of organ function. Minimizing calcineurin inhibitor (CNI)-related nephrotoxicity is a key component of this objective. Everolimus is a mammalian target of rapamycin inhibitor/proliferation-signal inhibitor with potent immunosuppressive and anti-proliferative effects. It has been widely investigated in large randomized clinical studies that have shown it to have similar anti-rejection efficacy compared with standard-of-care regimens across organ transplant indications. With demonstrated potential to facilitate the reduction of CNI therapy and preserve renal function, everolimus is an alternative to the current standard-of-care CNI-based regimens used in de novo and maintenance solid organ transplantation recipients. Here, we provide an overview of the evidence from the everolimus clinical study program across kidney, liver, heart, and lung transplants, as well as other key data associated with its use in CNI reduction strategies in adult transplant recipients.